Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217762 | 0.75 | CHRM3 (0.42) | CYP19A1KMT2ALMNA | |
| SCHEMBL14615743 | 0.74 | CYP2A6 (0.39) | CYP19A1KMT2ASMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL129440 | 0.68 | MLYCD (0.40) | ALDH1A1TP53HTTNOS1 | |
| SCHEMBL23425510 | 0.68 | CYP19A1 (0.38) | CYP19A1KMT2ASMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL14291433 | 0.68 | NPSR1 (0.40) | CYP19A1KMT2ASMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL23425483 | 0.67 | CYP19A1 (0.44) | CYP19A1KMT2ASMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL23425507 | 0.67 | CYP19A1 (0.51) | CYP19A1KMT2ASMN1; SMN2ALDH1A1CFTR | |
| Triphenylmethanol SCHEMBL6057181 | 0.66 | CYP19A1 (0.48) | CYP19A1KMT2AALDH1A1 | |
| SCHEMBL128024 | 0.66 | NOS1 (0.44) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL14151845 | 0.66 | NOS1 (0.50) | KMT2ASMN1; SMN2NPC1RAB9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| CN-101282949-B | Azole and thiazole derivatives and uses thereof | ARGENTA DISCOVERY LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| CN-101282949-A | Azole and thiazole derivatives and their use | ARGENTA DISCOVERY LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | CYP19A1 858/4885KMT2A 4199/4885SMN1; SMN2 4171/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | CYP19A1 1716/4885KMT2A 2826/4885SMN1; SMN2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.